Year: 2024
Type: article
Abstract: Attention‐deficit hyperactivity disorder (ADHD) is treated by medications, most recently, by viloxazine (Qelbree). Researchers in China looked at clinical trials to try to determine the best dose. Viloxazine was associated with better outcomes than placebo, with a bell‐shaped response curve suggesting that doses greater than 400 mg or greater than 7 mg/kg might not be linked to greater efficacy. Ascent curves tapered off about weeks 4 to 6. The curve for only 100 mg/d declined more rapidly, while the curves for 200 mg/dl and 400 mg/dl declined more gradually. In terms of adverse effects, there was a higher risk of discontinuation with viloxazine compared to placebo. The discontinuation rates due to adverse effects was 4.15% in the viloxazine group.
DOI: 10.1002/cpu30925
Author: Alison Knopf
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4405375044